Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 16 | 2025 | 1230 | 3.300 |
Why?
|
| Glucokinase | 6 | 2023 | 61 | 1.900 |
Why?
|
| Genetic Testing | 8 | 2023 | 566 | 1.810 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2021 | 594 | 1.400 |
Why?
|
| Insulin Infusion Systems | 2 | 2021 | 44 | 1.290 |
Why?
|
| Pancreas, Artificial | 2 | 2021 | 32 | 1.280 |
Why?
|
| Pregnancy in Diabetics | 2 | 2018 | 41 | 1.100 |
Why?
|
| Insulin | 6 | 2021 | 1191 | 1.080 |
Why?
|
| Hypoglycemic Agents | 7 | 2025 | 376 | 1.040 |
Why?
|
| Diabetes Mellitus | 8 | 2023 | 769 | 0.850 |
Why?
|
| Self-Management | 1 | 2021 | 44 | 0.670 |
Why?
|
| Mutation | 11 | 2023 | 4376 | 0.630 |
Why?
|
| Patient Participation | 1 | 2020 | 241 | 0.550 |
Why?
|
| Sulfonylurea Compounds | 7 | 2025 | 69 | 0.540 |
Why?
|
| Blood Glucose | 2 | 2025 | 873 | 0.530 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 273 | 0.510 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 500 | 0.480 |
Why?
|
| Registries | 6 | 2023 | 998 | 0.470 |
Why?
|
| Adolescent | 13 | 2024 | 9870 | 0.440 |
Why?
|
| Mass Screening | 1 | 2019 | 710 | 0.430 |
Why?
|
| Child | 11 | 2024 | 7625 | 0.420 |
Why?
|
| Adolescent Behavior | 1 | 2015 | 115 | 0.410 |
Why?
|
| Medication Adherence | 1 | 2015 | 122 | 0.410 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 5 | 2017 | 124 | 0.390 |
Why?
|
| Precision Medicine | 4 | 2023 | 456 | 0.390 |
Why?
|
| Models, Theoretical | 2 | 2019 | 504 | 0.360 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2024 | 14 | 0.320 |
Why?
|
| Blood Glucose Self-Monitoring | 2 | 2021 | 62 | 0.320 |
Why?
|
| Humans | 28 | 2025 | 95979 | 0.290 |
Why?
|
| Infant, Newborn | 8 | 2019 | 2614 | 0.290 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2019 | 157 | 0.270 |
Why?
|
| Hyperglycemia | 2 | 2019 | 181 | 0.270 |
Why?
|
| Genomics | 1 | 2013 | 857 | 0.260 |
Why?
|
| Female | 19 | 2025 | 49970 | 0.260 |
Why?
|
| Male | 18 | 2025 | 45783 | 0.240 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 3 | 2023 | 80 | 0.230 |
Why?
|
| Biomarkers | 3 | 2025 | 1932 | 0.230 |
Why?
|
| Young Adult | 6 | 2020 | 7024 | 0.230 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2025 | 11 | 0.230 |
Why?
|
| Child, Preschool | 6 | 2019 | 3973 | 0.230 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2023 | 5 | 0.200 |
Why?
|
| United States | 5 | 2021 | 7776 | 0.190 |
Why?
|
| Adult | 10 | 2025 | 28629 | 0.190 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 2 | 2013 | 30 | 0.190 |
Why?
|
| Life Expectancy | 2 | 2019 | 91 | 0.180 |
Why?
|
| Pregnancy | 2 | 2018 | 3237 | 0.170 |
Why?
|
| Computer Literacy | 1 | 2020 | 3 | 0.160 |
Why?
|
| Attitude to Computers | 1 | 2020 | 12 | 0.160 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 146 | 0.160 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 33 | 0.160 |
Why?
|
| Infant | 5 | 2019 | 3364 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2020 | 79 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2020 | 295 | 0.150 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 48 | 0.150 |
Why?
|
| Sleep | 1 | 2023 | 461 | 0.140 |
Why?
|
| Prevalence | 2 | 2024 | 1350 | 0.140 |
Why?
|
| Genetic Markers | 1 | 2019 | 477 | 0.140 |
Why?
|
| Birth Weight | 1 | 2018 | 152 | 0.140 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 161 | 0.140 |
Why?
|
| Siblings | 2 | 2016 | 109 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factors | 1 | 2018 | 2 | 0.140 |
Why?
|
| Abortion, Spontaneous | 1 | 2018 | 74 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2020 | 9230 | 0.130 |
Why?
|
| Pedigree | 1 | 2019 | 978 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2019 | 255 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2017 | 112 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 514 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2019 | 381 | 0.120 |
Why?
|
| Potassium Channels | 1 | 2018 | 359 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 570 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1817 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 539 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 683 | 0.110 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2016 | 116 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 41 | 0.110 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 208 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 1618 | 0.110 |
Why?
|
| Middle Aged | 7 | 2025 | 28295 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1873 | 0.100 |
Why?
|
| Trans-Activators | 1 | 2011 | 446 | 0.070 |
Why?
|
| Internet | 1 | 2011 | 340 | 0.070 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 563 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2013 | 3114 | 0.060 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 60 | 0.060 |
Why?
|
| Sulfonylurea Receptors | 2 | 2014 | 50 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2025 | 789 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2025 | 816 | 0.040 |
Why?
|
| Family | 1 | 2023 | 331 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2023 | 458 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2024 | 442 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10309 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 3922 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 137 | 0.030 |
Why?
|
| Cost Savings | 1 | 2017 | 71 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 191 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2017 | 125 | 0.030 |
Why?
|
| Prognosis | 1 | 2025 | 3994 | 0.030 |
Why?
|
| Neurologic Manifestations | 1 | 2016 | 11 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 38 | 0.030 |
Why?
|
| Glyburide | 1 | 2015 | 31 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 336 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2016 | 302 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 345 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 548 | 0.030 |
Why?
|
| Risk Factors | 1 | 2023 | 5984 | 0.020 |
Why?
|
| Receptors, Drug | 1 | 2011 | 52 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1962 | 0.020 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 23 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 142 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1967 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2011 | 101 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1958 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 2576 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2010 | 382 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1176 | 0.020 |
Why?
|
| Aged | 2 | 2017 | 20920 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1722 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1505 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 2019 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 28905 | 0.010 |
Why?
|